Procurement Inclusion Criteria:

Participants must meet the protocol-defined procurement eligibility criteria before collection of peripheral blood mononuclear cells for manufacture of the investigational product, including:

1. Diagnosis of relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma.
2. CD30 positive tumor (can be pending at this time) as assayed in a CLIA certified Pathology Laboratory.
3. Age 16 to 75 years.
4. Hemoglobin ≥7.0(may be transfused value).
5. Karnofsky or Lansky score of > 60%
6. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given copy of informed consent.

Procurement Exclusion Criteria:

1. Active HIV or HTLV infection (testing may be pending at procurement).

2. Active bacterial, fungal, or viral infection.

   ____________________________________________________________________________

Treatment Inclusion Criteria:

Participants with a successfully manufactured product must continue to satisfy the protocol-defined treatment eligibility criteria before receiving study treatment, including:

1. Diagnosis and clinical course falling into one of the following categories:

   • Hodgkin lymphoma
   • CD30+ aggressive B-cell lymphoma
   • ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma
   • ALK-positive anaplastic T cell lymphoma

2. CD30 expression confirmed in a CLIA-certified laboratory. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy

3. Age 16 to 75 years.

4. Bilirubin ≤ 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin ≤ 3 times the upper limit of normal).

5. AST ˂ 3 times the upper limit of normal

6. Estimated GFR > 50 mL/min

7. Pulse oximetry of > 90% on room air

8. Karnofsky or Lansky score of > 60%

9. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after study is concluded. Male partner should use a condom

10. Informed consent explained to, understood by and signed by patient/guardian. Patient/Guardian given copy of informed consent.

Treatment Exclusion Criteria:

1. Received an investigational cell therapy or vaccine within the past 6 weeks.
2. Received an investigational small molecule within the past 2 weeks.
3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.
4. History of hypersensitivity reactions to murine protein-containing products
5. Pregnancy or breastfeeding.
6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion)
7. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone.
8. Active significant, uncontrolled bacterial, viral or fungal infection.
9. Symptomatic cardiac disease (NYHA Class III or IV disease).